-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The UK's National Institute for Health and Care Excellence (NICE) recommends immunotherapy Bavncio (avelumab) as a maintenance treatment option for eligible adult patients with locally advanced metastatic urothelial carcinoma (UC)
immunity
Bladder cancer generally refers to various malignant tumors arising from the bladder
diagnosis
NICE's decision marks avelumab as the first and only monotherapy for first-line maintenance therapy in adult patients with locally advanced or metastatic UC who have not progressed after platinum-based chemotherapy
A phase III trial enrolled patients with unresectable locally advanced or metastatic urothelial carcinoma
The 1-year overall survival rate was 71.
Figure 1.
OS in the avelumab group vs.
Original source:
Original source:https:// href="https://" target="_blank" rel="noopener">https:// https://